$0.16
2.75%
Downside
Day's Volatility :5.46%
Upside
2.79%
34.19%
Downside
52 Weeks Volatility :96.37%
Upside
94.48%
Period | Apollomics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -17.28% | 0.0% |
6 Months | -71.79% | 0.0% |
1 Year | -93.97% | 0.0% |
3 Years | -99.46% | -21.4% |
Market Capitalization | 17.4M |
Book Value | $0.19 |
Earnings Per Share (EPS) | -0.15 |
Wall Street Target Price | 2.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1431.62% |
Return On Assets TTM | -62.74% |
Return On Equity TTM | -149.31% |
Revenue TTM | 2.1M |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | 262.3% |
Gross Profit TTM | 0.0 |
EBITDA | -53.1M |
Diluted Eps TTM | -0.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | -0.65 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 1150.0%
Sell
Neutral
Buy
Apollomics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Apollomics Inc | 15.84% | -71.79% | -93.97% | -99.46% | -99.46% |
Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
Alnylam Pharmaceuticals, Inc. | 6.47% | 71.74% | 59.21% | 32.07% | 248.13% |
Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Apollomics Inc | NA | NA | NA | 0.0 | -1.49 | -0.63 | NA | 0.19 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Apollomics Inc | Buy | $17.4M | -99.46% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Insights on Apollomics Inc
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 146.1%
formerly known as cbt pharmaceuticals. at apollomics, we are a purpose driven company imagining a world without cancer. we let science drive our decision making to advance our programs. we believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve. apollomics is committed to the discovery and development of oncology combination therapies. we believe that combination regimens can achieve clinically meaningful, durable responses that will allow us to enhance outcomes for patients. we have in-licensed our assets from multiple partners and built strong collaborations to advance our pre-clinical and clinical development programs. when developing an asset, we begin with rigorous ind-enabling studies to establish sound mechanistic and scientific rationale and guide our development path. this path may be as a monotherapy, a combination therapy, or both. while our ultimate goal is to study each of our assets in combination with other agents, we h
Organization | Apollomics Inc |
Employees | 45 |
CEO | Dr. Guo-Liang Yu Ph.D. |
Industry | Miscellaneous |
Generations Bancorp Ny Inc
$0.16
-3.66%
Utime Ltd
$0.16
-3.66%
Ncs Multistage Holdings Inc
$0.16
-3.66%
Aam Brentview Dividend Growth Etf
$0.16
-3.66%
Invesco Nasdaq Next Gen 100 Etf
$0.16
-3.66%
Cohen & Steers Tax-advantage
$0.16
-3.66%
Sim Acquisition Corp I-a
$0.16
-3.66%
Victoryshares Westend Global Equity Etf
$0.16
-3.66%
Flotek Industries Inc
$0.16
-3.66%